Oncternal Therapeutics

📍 San Diego, United States🗓 Founded 2013👥 39 employees💰 Last funded Jun 2019
Biotechnology🌐 oncternal.com
Website LinkedIn
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Oncternal Therapeutics?
Oncternal Therapeutics has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did Oncternal Therapeutics last raise funding?
The most recent investment in Oncternal Therapeutics recorded on gritt.io was in June 2019.
When was Oncternal Therapeutics founded?
Oncternal Therapeutics was founded in 2013.
What industry is Oncternal Therapeutics in?
Oncternal Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Oncternal Therapeutics based?
Oncternal Therapeutics is headquartered in San Diego, United States.